Nebimel (Nebivolol)

Nebivolol, the active ingredient in Nebimel, is a beta‑blocker presented as a tablet for oral use. It treats hypertension and heart failure in adult patients.\n\nGNH India supplies Nebimel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.\n\nHypertension: lowers blood pressure by reducing cardiac output and promoting vasodilation.\nHeart failure (reduced ejection fraction): improves ventricular function and reduces symptoms.\nLeft ventricular systolic dysfunction: helps restore normal cardiac performance and decreases hospitalization risk.

Nebivolol may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Fatigue or tiredness\n- Headache\n- Dizziness, especially when standing\n- Bradycardia (slow heart rate)\n- Nausea or mild gastrointestinal upset\n\nSerious or Rare Side Effects:\n- Severe bradycardia or heart block\n- Marked hypotension\n- Bronchospasm in patients with reactive airway disease\n- Allergic reactions such as rash, angioedema, or anaphylaxis\n- Worsening heart failure symptoms

Before initiating Nebivolol, clinicians should consider several safety aspects.\n\nMonitor blood pressure: ensure adequate control without excessive drop.\nMonitor heart rate: watch for bradycardia, especially in patients with conduction disorders.\nUse caution in asthma or COPD: β‑blockade may precipitate bronchospasm.\nAdjust dose in hepatic impairment: reduced clearance may increase exposure.\nAvoid abrupt discontinuation: taper to prevent rebound hypertension.\nStore at ambient temperature: keep in the original pack, protect from moisture.

Nebivolol can interact with several drug classes, requiring careful management.\n\nMajor Interactions (Avoid):\n- Concomitant use with other β‑blockers: risk of excessive bradycardia.\n- Calcium‑channel blockers verapamil or diltiazem: additive negative inotropic effects.\n- Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma levels.\n- Insulin or oral hypoglycemics: may enhance hypoglycaemia.\n- Clonidine withdrawal: can cause rebound hypertension.\n\nModerate Interactions (Monitor Closely):\n- NSAIDs: may blunt antihypertensive effect.\n- Diuretics: monitor electrolytes and blood pressure.\n- Other antihypertensives: assess for additive hypotensive response.\n- Digoxin: observe for bradyarrhythmias.\n- Certain antidepressants (e.g., sertraline): watch for heart rate changes.